UNIMED, TN0007720014

UNIMED stock: UNIMED reports TND 32.20 million revenue. Investing.com rates UNIMED stock Sell

Published on 10/24/2026 at 01:21 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UNIMED reported TND 32.20 million in third-quarter 2026 revenue, down 24.70 percent. For UNIMED stock, third-quarter 2025 revenue was TND 42.70 million.

Revenue and valuation signals

Third-quarter 2026 revenue came to TND 32.20 million, down 24.70 percent year over year.
Investing.com lists one analyst target of TND 10.60 and a Sell consensus.
Irbe7 describes UNIMED as a sterile-drug manufacturer founded in 1989.

UNIMED, TN0007720014, Illustration mit AI erstellt.

UNIMED (ISIN TN0007720014) reported TND 32.20 million in third-quarter 2026 revenue, down 24.70 percent from TND 42.70 million a year earlier, according to Mizen on October 22, 2026. Investing.com lists one analyst rating the stock Sell and a 12-month target of TND 10.60.

What does the revenue drop mean?

The year-over-year comparison puts the latest operating signal in clear numerical terms: UNIMED generated TND 10.50 million less revenue than in third-quarter 2025. The decline is the central company-specific figure for investors assessing the stock after the filing deadline for Tunisian listed companies.

Mizen's table identifies UNIMED under the ticker UMED and reports the figures in TND. The company makes sterile medicines, a specialization that requires controlled manufacturing processes, according to Irbe7.

One target sets a valuation marker

The analyst view provides a counterpoint to the revenue contraction. Investing.com records one Sell rating and a TND 10.60 target, while its summary reports a TND 8.65 quote and a TND 7.90 to TND 11.00 52-week range on its market pages. The target stands 22.54 percent above the TND 8.65 quote, calculated from the two TND values shown in the cited pages.

That valuation marker is not a forecast from this article. It shows how the available analyst view compares with a dated Tunis market quote, while the latest operating figure points to weaker year-over-year sales. The combination gives the stock a measurable tension between valuation and near-term revenue performance.

UNIMED remains a Tunisian pharmaceutical listing

Investing.com identifies Unite de Fabrication de Medicaments SA as a Tunis-listed pharmaceutical company with 572 employees. Irbe7 states that the business was founded in 1989 and entered the Tunis market on May 4, 2016.

Revenue remains the key stock variable

For investors, the next assessment of UNIMED will center on whether quarterly revenue can recover from the TND 32.20 million reported for third-quarter 2026. The TND 10.60 analyst target supplies a valuation reference, but the 24.70 percent year-over-year decline remains the clearest operating comparison in the latest report.